Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)
Rhea-AI Summary
Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.
The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.
Full Q2 2025 results will be released around August 8th, 2025.
Positive
- Record Q2 revenue of $10.1-$10.2 million, up 41-42% year-over-year
- First half 2025 revenue growth of 50-51% compared to first half 2024
- Complete national sales territory coverage with 13 sales representatives
- Addition of dedicated national accounts manager for larger market opportunities
Negative
- Company in transition period with recent management changes
- Final Q2 results subject to adjustments pending financial close process
News Market Reaction
On the day this news was published, SNWV declined 7.99%, reflecting a notable negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $25M from the company's valuation, bringing the market cap to $289M at that time.
Data tracked by StockTitan Argus on the day of publication.
Sanuwave is pleased to announce preliminary revenues of
Q2 2025 revenue increased between
First half of 2025 revenue increased 50
EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2025 are expected to be in the range of
“We’re pleased to once more be on guidance and on track for Q2 and for the first half of 2025,” said CEO Morgan Frank. “As we mentioned last quarter, the first half of 2025 has been a transition period for the company as we have added a new head of sales and now a new head of commercial operations. Q2 was really the “max transition” period as we have been staffing up rapidly and will, in July, reach 13 sales people and for the first time in my tenure as CEO have all of our national sales territories covered. We have also added a key national accounts manager to be our dedicated “elephant hunter” in order to better pursue some of the larger opportunities in our market. This has been a period of taking the plane apart and putting it back together all while flying it quite fast, and the team has come through in phenomenal fashion. We’re all very excited about what we’re building here, our pipeline, and the prospects for the year and years ahead. The Company plans to release its full Q2 results on or around August 8th, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
The preliminary revenue results described herein are based on management’s initial analysis of the second quarter ended June 30, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What were Sanuwave Health's (SNWV) preliminary Q2 2025 revenue results?
How much did Sanuwave's revenue grow in the first half of 2025?
When will Sanuwave (SNWV) release its full Q2 2025 earnings report?
How many sales representatives will Sanuwave have by July 2025?
What recent management changes has Sanuwave (SNWV) made in 2025?
